Phaseline

Companies › Arch Biopartners

Arch Biopartners: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Cardiovascular; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
LSALT Peptide
Binds to dipeptidase-1 (DPEP1) and inhibits leukocyte recruitment
DPEP1Phase 2Acute Kidney InjuryMar 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05879432LSALT PeptidePhase 2Acute Kidney InjuryCardiovascularMar 2027

Targets

DPEP1 (1)

Companies with the same targets

–

Companies built like this

Merakris Therapeutics OHB Neonatology Nyrada AllRock Bio Zomagen Biosciences

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.